<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000688</url>
  </required_header>
  <id_info>
    <org_study_id>VILD1</org_study_id>
    <nct_id>NCT01000688</nct_id>
  </id_info>
  <brief_title>Vildagliptin and Endothelium-dependent Vasodilatation</brief_title>
  <official_title>The Effect of Vildagliptin on Endothelium-dependent Vasodilatation. A Double Blind Cross-over Study in Type 2 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Cardiovascular complications in type 2 diabetes are the leading cause of morbidity
      and mortality associated with the disease. Endothelial dysfunction is regarded as an
      important factor in these vascular complications.

      The introduction of glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase IV
      (DPP-IV) inhibitors for the treatment of type 2 diabetes is of special interest because of
      possible influences on endothelial function. Numerous reports have shown that GLP-1 improves
      endothelial function.

      Objective: To determine whether a four week treatment with vildagliptin compared to acarbose
      improves endothelial dysfunction in patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forearm vasodilator response to intra-arterial infusion of acetylcholine (endothelium-dependent) following treatment with vildagliptin and following active control with acarbose</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of vildagliptin on inflammatory markers and adipokines</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of vildagliptin on fat cell morphology and gene expression</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of vildagliptin on ex vivo mononuclear cell responses to various stimuli</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>vildagliptin treatment first, acarbose treatment second</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>acarbose treatment first, vildagliptin treatment second</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vildagliptin + acarbose</intervention_name>
    <description>4 week treatment</description>
    <arm_group_label>vildagliptin treatment first, acarbose treatment second</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acarbose + vildagliptin</intervention_name>
    <description>4 week treatment</description>
    <arm_group_label>acarbose treatment first, vildagliptin treatment second</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Age 35-75 years

          -  Treatment with metformin monotherapy or metformin combination therapy

          -  HbA1c &lt;8.0%

        Exclusion Criteria:

          -  Renal disease defined as creatinine level &gt; 130 umol/l

          -  Liver disease defined as aspartate aminotransferase or alanine aminotransferase level
             of more than three times the upper limit of normal range

          -  Current use of acetylsalicylic acid or vitamine K antagonists

          -  History of smoking within the past year

          -  History of or current abuse of drugs or alcohol

          -  History of heartfailure (NYHA class III or IV)

          -  Abnormalities on ECG that might interfere with current study protocol

          -  Pregnancy or breastfeeding

          -  Inability to understand the nature and extent of the trial and procedures required

          -  Presence of any medical condition that might interfere with the current study protocol

          -  Participation in a drug trial within 60 days prior to the first dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C.J. Tack, MD, PhD, Prof. of Diabetology</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <last_update_submitted>November 4, 2010</last_update_submitted>
  <last_update_submitted_qc>November 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. C.J. Tack</name_title>
    <organization>UMC St Radboud</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

